PolioNCT02376374
OPV Transmissibility in Communities After Cessation of Routine OPV Immunization
A study of Polio, run by Stanford University.
Trial summary
The investigators propose to study both inter- and intra-household Oral Polio Vaccine (OPV) transmission in a primarily inactivated-polio vaccine (IPV)-vaccinated community in Mexico. Read more about this study
- Who is it for?
- Ages Up to 59 months
- Conditions the study is for
- Polio
- Type of treatment
- Vaccines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,828 participants
- Where
- No sites listed yet
- Study dates
- Feb 2015to 31 Mar 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 59 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Households with children under the age of 5 who have up-to-date IPV vaccination history and willing to give informed consent and/or assent.
Who cannot join
- Unwilling/unable to bring children's IPV vaccination records up-to-date.
About this study
The investigators propose to study both inter- and intra-household Oral Polio Vaccine (OPV) transmission in a primarily inactivated-polio vaccine (IPV)-vaccinated community in Mexico. The investigators will enroll 3 distinct clusters of households in a municipality in Orizaba, Veracruz, Mexico prior to the February 2015 National Immunization Week (NIW.) These clusters will be physically separate from one another and differ only in the proportion of OPV-eligible children who will receive OPV during the February 2015 NIW (10%, 30% and 70% vaccinated.) The investigators will look at inter-household and intra-household transmission. The investigators will then determine if epidemiologic (i.e.: degree of contact), anthropometric (i.e.: nutritional status) or clinical covariates (i.e.: IPV/OPV immunization history) are associated with intra-household transmission.
Read the detailed description
We propose a prospective study to be conducted in 3 distinct clusters of 150 households each in one semi-urban municipality in Orizaba, Veracruz, Mexico during and after the February 2015 National Immunization Week (NIW.) Mexico provides a unique environment to study OPV transmission. The last case of poliomyelitis was reported in 1990. Mexico transitioned from an OPV to an IPV-based immunization regimen in 2007-2008. Currently, Mexican children receive IPV at 2, 4, 6, and 18 months of age. In addition, children ≤5 years old who have received at least 2 doses of IPV are eligible to receive OPV during biannual NIW held in February and May each year. Because of the changes in vaccination regimens over time, Mexican households consist of individuals with different degrees of susceptibility to OPV infection: those born before 2007 who were exposed to WPV and OPV or OPV alone, those born after 2007 exposed to IPV with intermittent OPV exposure, and un-vaccinated infants, some with maternal polio virus antibodies. By studying OPV transmission in this setting, we will be able to assess the impact of differing immunization status on OPV shedding and transmission.
We will conduct our study in a relatively isolated and semi-urban municipality of Orizaba, Veracruz, Mexico. These household clusters will differ only in the proportion of OPV-eligible children who will be OPV-vaccinated during the February 2015 National Immunization Week (10%, 30% and 70%.) We will enroll households that have at least 1 healthy child less than 5 years of age with an up-to-date IPV vaccination history. Enrolled households will then be randomized to the OPV-vaccinated or non-vaccinated arm of each household cluster. Eligible children from households in the OPV-vaccinated arm will then be further randomized to either receive OPV or remain un-vaccinated. Thus, only one child per household in the OPV-vaccinated arm will be vaccinated.
We will collect stool samples from all members of the enrolled households serially over the course of the study and will determine if individuals shed OPV in their stool using a serotype-specific real-time polymerase chain reaction (PCR) assay. We will define inter-household transmission as fecal OPV shedding by any member of a non-vaccinated household. By comparing inter-household transmission rates among all the household clusters, we will determine the if the proportion of OPV-vaccinated children impacts community OPV transmission in a primarily IPV-vaccinated community. These results will be critical to predicting the risk of OPV re-introduction in the event of a poliomyelitis outbreak in the post-OPV era.
We will define intra-household transmission as OPV shedding by household contacts living in vaccinated households. We will examine intra-household transmission in all clusters together to determine if certain characteristics are associated with transmission to household contacts. Elucidating these characteristics would allow for targeted interventions to reduce or prevent OPV transmission as cessation policy is implemented or in the event that OPV re-introduction is needed during polio endgame.
- Conditions
- Polio
- Being tested
- Controlling vaccination rates in communities
- Keywords
- transmission, vaccine
- Medical subject headings
- Poliomyelitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Controlling vaccination rates in communitiesOther
Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
| Study group | Role | What they receive |
|---|---|---|
| 10% OPV | Experimental | In this arm, 10% of the households in this community will receive OPV. Receives: Other: Controlling vaccination rates in communities |
| 30% OPV | Experimental | In this arm, 30% of the households in this community will receive OPV. Receives: Other: Controlling vaccination rates in communities |
| 70% OPV | Experimental | In this arm, 70% of the households in this community will receive OPV. Receives: Other: Controlling vaccination rates in communities |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inter-household transmission of poliovirus
Measured: Feb 2015-May 2015; 4 months
Intra-household transmission of poliovirus
Measured: Feb 2015-May 2015; 4 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2015 (estimated)
- Study startFeb 2015
- Primary completion28 Feb 2017
- Study completion31 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PolioStudies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,828 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation, Instituto Nacional de Salud Publica, Mexico
- Responsible party
- Principal investigator, Yvonne (Bonnie) A Maldonado, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02376374
- Sponsor's protocol ID
- 31546
- Status last verified
- May 2019
- First submitted
- 18 Feb 2015
- Last updated
- 16 May 2019
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 May 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- OPV Transmissibility in Communities After Cessation of Routine OPV Immunization
- ClinicalTrials.gov ID
- NCT02376374
- Acronym / sponsor ID
- 31546
- Conditions
- Polio
- Keywords
- transmission, vaccine
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,828 participants (actual)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation, Instituto Nacional de Salud Publica, Mexico
- Study start
- Feb 2015
- Primary completion
- 28 Feb 2017 (actual)
- Study completion
- 31 Mar 2019 (actual)
- First posted
- 3 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators propose to study both inter- and intra-household Oral Polio Vaccine (OPV) transmission in a primarily inactivated-polio vaccine (IPV)-vaccinated community in Mexico. The investigators will enroll 3 distinct clusters of households in a municipality in Orizaba, Veracruz, Mexico prior to the February 2015 National Immunization Week (NIW.) These clusters will be physically separate from one another and differ only in the proportion of OPV-eligible children who will receive OPV during the February 2015 NIW (10%, 30% and 70% vaccinated.) The investigators will look at inter-household and intra-household transmission. The investigators will then determine if epidemiologic (i.e.: degree of contact), anthropometric (i.e.: nutritional status) or clinical covariates (i.e.: IPV/OPV immunization history) are associated with intra-household transmission.
Detailed description
We propose a prospective study to be conducted in 3 distinct clusters of 150 households each in one semi-urban municipality in Orizaba, Veracruz, Mexico during and after the February 2015 National Immunization Week (NIW.) Mexico provides a unique environment to study OPV transmission. The last case of poliomyelitis was reported in 1990. Mexico transitioned from an OPV to an IPV-based immunization regimen in 2007-2008. Currently, Mexican children receive IPV at 2, 4, 6, and 18 months of age. In addition, children ≤5 years old who have received at least 2 doses of IPV are eligible to receive OPV during biannual NIW held in February and May each year. Because of the changes in vaccination regimens over time, Mexican households consist of individuals with different degrees of susceptibility to OPV infection: those born before 2007 who were exposed to WPV and OPV or OPV alone, those born after 2007 exposed to IPV with intermittent OPV exposure, and un-vaccinated infants, some with maternal polio virus antibodies. By studying OPV transmission in this setting, we will be able to assess the impact of differing immunization status on OPV shedding and transmission.
We will conduct our study in a relatively isolated and semi-urban municipality of Orizaba, Veracruz, Mexico. These household clusters will differ only in the proportion of OPV-eligible children who will be OPV-vaccinated during the February 2015 National Immunization Week (10%, 30% and 70%.) We will enroll households that have at least 1 healthy child less than 5 years of age with an up-to-date IPV vaccination history. Enrolled households will then be randomized to the OPV-vaccinated or non-vaccinated arm of each household cluster. Eligible children from households in the OPV-vaccinated arm will then be further randomized to either receive OPV or remain un-vaccinated. Thus, only one child per household in the OPV-vaccinated arm will be vaccinated.
We will collect stool samples from all members of the enrolled households serially over the course of the study and will determine if individuals shed OPV in their stool using a serotype-specific real-time polymerase chain reaction (PCR) assay. We will define inter-household transmission as fecal OPV shedding by any member of a non-vaccinated household. By comparing inter-household transmission rates among all the household clusters, we will determine the if the proportion of OPV-vaccinated children impacts community OPV transmission in a primarily IPV-vaccinated community. These results will be critical to predicting the risk of OPV re-introduction in the event of a poliomyelitis outbreak in the post-OPV era.
We will define intra-household transmission as OPV shedding by household contacts living in vaccinated households. We will examine intra-household transmission in all clusters together to determine if certain characteristics are associated with transmission to household contacts. Elucidating these characteristics would allow for targeted interventions to reduce or prevent OPV transmission as cessation policy is implemented or in the event that OPV re-introduction is needed during polio endgame.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 10% OPV | Experimental | Other: Controlling vaccination rates in communitiesIn this arm, 10% of the households in this community will receive OPV. |
| 30% OPV | Experimental | Other: Controlling vaccination rates in communitiesIn this arm, 30% of the households in this community will receive OPV. |
| 70% OPV | Experimental | Other: Controlling vaccination rates in communitiesIn this arm, 70% of the households in this community will receive OPV. |
Who may qualify
- Ages
- Up to 59 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Households with children under the age of 5 who have up-to-date IPV vaccination history and willing to give informed consent and/or assent.
Key exclusion criteria (1 listed)
- Unwilling/unable to bring children's IPV vaccination records up-to-date.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Controlling vaccination rates in communitiesThree communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community. | Other | 10% OPV, 30% OPV, 70% OPV |
Primary outcome
Inter-household transmission of poliovirus
Time frame: Feb 2015-May 2015; 4 months
Intra-household transmission of poliovirus
Time frame: Feb 2015-May 2015; 4 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 May 2019.
Related trials for Polio
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingPhase 1/2
A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed
Diphtheria, Pertussis
Not yet recruitingPhase 1/2
Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)
Diptheria Immunization, Tetanus Immunization
RecruitingPhase 1
Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
Polio Immunity
Active, not recruiting
Effects of Virtual Walking on Chronic Pain and Psychological Distress for Individuals With Severe Mobility Impairment
Severe Mobility Impairment, Spinal Cord Injuries (SCI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study of Polio, run by Stanford University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 May 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inter-household transmission of poliovirus (time frame: Feb 2015-May 2015; 4 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2019.